XPERT MRSA/SA BC GXMRSA/SA-BC-10

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 05,06,07 report with the FDA on 2010-05-04 for XPERT MRSA/SA BC GXMRSA/SA-BC-10 manufactured by Cepheid.

Event Text Entries

[1494861] On april 1, a (b) (6) male was admitted to hospital complaining of back pain; pt had a history of renal insufficiency and congestive heart failure. On april 6, pt becomes febrile, blood was drawn for blood culture and test was positive by cepheid gx (b) (6)/sa bc assay for (b) (6). On april 7, pt was treated with invanz (ertapenem) antibiotic; pt fell in room, hit head, cardiac arrest, was revived and sent to icu; nasal swab taken for (b) (6) culture test; pt given 1500 mg vancomycin. On april 8, pt was given oxacillin. On april 9, blood culture agar plate was positive for (b) (6) and april 6, culture sample repeated on cepheid gx (b) (6)/sa bc test was now (b) (6) positive; hospital lab contacted cepheid to report the discrepancy in test results (b) (4). On april 11, the pt expired. On april 28, a meeting was held between hospital lab personnel and cepheid personnel to review the details of the complaint during which cepheid learned for first time pt had died. Cepheid began mdr process following internal procedure as specified in (b) (4) (medical device reporting sop. On april 29 and april 30 follow up meetings were held with lab pathologist dr (b) (6) to confirm details of complaint.
Patient Sequence No: 1, Text Type: D, B5


[8645154] Intended use of device: the cepheid xpert (b) (6) blood culture assay performed on the genexpert dx system is a qualitative in vitro diagnostic test intended for the detection of (b) (6) and (b) (6) dna directly from pt positive blood cultures. The assay utilizes automated real-time polymerase chain reaction (pcr) for the amplification of (b) (6) specific dna targets and fluorogenic target-specific hybridization probes for the real-time detection of the amplified dna. The assay is performed directly on positive blood culture specimens using bd bactec plus aerobic/f blood culture bottles that are determined as gram positive (b) (6) in clusters (b) (6) or as gram positive (b) (6) in singles (b) (6) by gram stain. The cepheid xpert (b) (6) blood culture assay is not intended to monitor treatment for (b) (6) infections. Subculturing of positive blood cultures is necessary to recover organisms for susceptibility testing or for epidemiological typing. Cepheid contact for mdr: (b) (4), vice president, regulatory compliance & quality systems, cepheid. (b) (4). (b) (4)
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number3004530258-2010-00001
MDR Report Key1675196
Report Source05,06,07
Date Received2010-05-04
Date of Report2010-05-03
Date of Event2010-04-11
Date Mfgr Received2010-04-09
Device Manufacturer Date2010-01-29
Date Added to Maude2010-05-06
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer Street904 CARIBBEAN DRIVE
Manufacturer CitySUNNYVALE CA 94089
Manufacturer CountryUS
Manufacturer Postal94089
Manufacturer Phone4085414191
Single Use3
Remedial ActionRC
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameXPERT MRSA/SA BC
Generic NameNONE
Product CodeNQX
Date Received2010-05-04
Catalog NumberGXMRSA/SA-BC-10
Lot Number1302
Device Expiration Date2011-05-29
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerCEPHEID
Manufacturer Address904 CARIBBEAN DRIVE SUNNYVALE CA 94089 US 94089


Patients

Patient NumberTreatmentOutcomeDate
101. Death 2010-05-04

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.